Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice  

作　　者：Mingqing Lu Kunpeng Liu Yun Peng Zhe Ding Yingwen Li Alexander Tendu Xue Hu Ge Gao Weiwei Guo Hang Liu Juhong Rao Jiaxuan Zhao Miaoyu Chen Zhiming Yuan Gary Wong Chao Shan Yanfeng Yao Jiaming Lan 

机构地区：[1]CAS Key Laboratory of Molecular Virology&Immunology,Institut Pasteur of Shanghai,Chinese Academy of Sciences,Shanghai,200031,China [2]State Key Laboratory of Virology,Chinese Academy of Sciences,Wuhan,430071,China [3]University of Chinese Academy of Sciences,Beijing,100049,China [4]Center for Biosafety Mega-Science,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China

出　　处：《Virologica Sinica》2022年第4期581-590,共10页中国病毒学（英文版）

基　　金：the National Natural Science Foundation of China(No.32070933 to J.M.Lan and Y.F.Yao);the Natural Science Foundation of Shanghai(No.20ZR1463900 to J.M.Lan);financially the STS regional key project(KFJ-STS-QYZD-2021-12-001 to Z.M.Yuan and C.Shan)from Chinese Academy of Sciences;National Key R&D Program of China 2021YFE0201900 to C.Shan and 2021YFC0863300 to Z.M.Yuan and C.Shan;the National Key R&D Program of China(No.2021YFC0863400);funding from Institut Pasteur,Fondation Merieux and the Chinese Academy of Sciences to G.W。

摘　　要：SARS-CoV-2 infection is a global public health threat.Vaccines are considered amongst the most important tools to control the SARS-CoV-2 pandemic.As expected,deaths from SARS-CoV-2 infection have dropped dramatically with widespread vaccination.However,there are concerns over the duration of vaccine-induced protection,as well as their effectiveness against emerging variants of concern.Here,we constructed a recombinant chimpanzee adenovirus vectored vaccine expressing the full-length spike of SARS-CoV-2(Ad C68-S).Rapid and high levels of humoral and cellular immune responses were observed after immunization of C57BL/6J mice with one or two doses of Ad C68-S.Notably,neutralizing antibodies were observed up to at least six months after vaccination,without substantial decline.Single or double doses Ad C68-S immunization resulted in lower viral loads in lungs of mice against SARS-CoV-2 challenge both in the short term(21 days)and long-term(6 months).Histopathological examination of Ad C68-S immunized mice lungs showed mild histological abnormalities after SARS-CoV-2 infection.Taken together,this study demonstrates the efficacy and durability of the Ad C68-S vaccine and constitutes a promising candidate for clinical evaluation.

关 键 词：SARS-CoV-2 VACCINE Chimpanzee adenovirus vector Neutralizing antibodies Long-term protection 

分 类 号：R392-33[医药卫生—免疫学]